Cargando…

Durability of Bivalent Boosters against Omicron Subvariants

Detalles Bibliográficos
Autores principales:	Lin, Dan-Yu, Xu, Yangjianchen, Gu, Yu, Zeng, Donglin, Sunny, Shadia K., Moore, Zack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120009/ https://www.ncbi.nlm.nih.gov/pubmed/37043647 http://dx.doi.org/10.1056/NEJMc2302462

Ejemplares similares

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Effects of Vaccination and Previous Infection on Omicron Infections in Children
por: Lin, Dan-Yu, et al.
Publicado: (2022)

Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

BF.7 Omicron subvariant in India and China: a raising concern – correspondence
por: Sah, Ranjit, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
por: Wang, Rui, et al.
Publicado: (2022)

The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pag34trnn2g3c1khniel6eb1au